Squarepoint’s Melinta Therapeutics MLNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-5,342
Closed -$106K – 2396
2018
Q3
$106K Buy
5,342
+2,774
+108% +$70.1K ﹤0.01% 1878
2018
Q2
$82K Sell
2,568
-852
-25% -$30.7K ﹤0.01% 1657
2018
Q1
$127K Buy
+3,420
New +$225K ﹤0.01% 1555

Other funds holding MLNT

Squarepoint's MLNT Position: Q4 2018 in Review

Squarepoint sold out of Melinta Therapeutics (MLNT) in Q4 2018, closing a stake of 5,342 shares — an estimated $106K sold.

Squarepoint first reported a position in MLNT in Q1 2018 and held it in 3 quarters. The position peaked at $127K in Q1 2018. 77 funds tracked by Wall St. Rank hold MLNT as of Q4 2018.

  • Squarepoint reported no remaining Melinta Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Squarepoint sold 5,342 Melinta Therapeutics shares in Q4 2018, an estimated $106K.
  • Squarepoint first reported a position in Melinta Therapeutics in Q1 2018 and held it in 3 quarters.
  • Squarepoint's Melinta Therapeutics position peaked at $127K in Q1 2018.
  • 77 funds tracked by Wall St. Rank held Melinta Therapeutics as of Q4 2018.

Based on Squarepoint's 13F filing for Q4 2018, filed 14 Feb 2019.